Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

Objectives: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- interleukin 6 receptor antibody) might interrupt the hy...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Matilde Sánchez-Conde, Pilar Vizcarra, José Manuel Pérez-García, María Gion, María Pilar Martialay, Javier Taboada, Alberto Alonso-Fernández, Miguel Sampayo-Cordero, Andrea Malfettone, Isabel Tena, Sergio De La Torre, Antonio Llombart-Cussac, Javier Cortés
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2022-10-01
Seri Bilgileri:	International Journal of Infectious Diseases
Konular:	Pembrolizumab Tocilizumab COVID-19 SARS-CoV-2 infection
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S1201971222004751
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

Benzer Materyaller